tbuckley/cabot-search huggingface dataset:
Cap-assisted forward-viewing endoscopy to visualize the ampulla of Vater and the duodenum in patients with familial adenomatous polyposis
Authors: Frank Kallenberg, Barbara Bastiaansen, Evelien Dekker
Journal: Endoscopy (2016)

<b>Background and study aims</b> Guidelines recommend surveillance endoscopy with both forward- and side-viewing endoscopes to identify duodenal and ampullary adenomas in patients with familial adenomatous polyposis (FAP). We hypothesized that both the duodenum and the ampulla of Vater can be completely visualized during cap-assisted forward-viewing endoscopy. <b>Patients and methods</b> A total of 40 patients with FAP underwent forward-viewing endoscopy with a short cap attached to the tip of the gastroscope, with the aim of visualizing both the duodenum and the ampulla of Vater. If unsuccessful, the procedure was followed by a side-viewing endoscopy. Adverse events were reported. <b>Results</b> The duodenum, including the ampulla of Vater, was completely visualized using the cap in 38/40 patients (95.0 %). The ampulla could not be visualized using the cap in two patients, both of whom underwent additional side-viewing endoscopy, which was successful. No adverse events occurred. <b>Conclusions</b> This study showed that cap-assisted endoscopy can be used effectively and safely to visualize both the duodenum and the ampulla of Vater in patients with FAP. This practice might reduce burden, time, and costs of an additional side-viewing endoscopy.
Abstract C11: The role of immune cells and androgen receptor splice variant 567 exon-skipping in prostate cancer
Authors: Jared HL Hara, Stephen R. Plymate, Cynthia T. Sprenger
Journal: Cancer Research (2016)

Abstract Importance: Nearly all metastatic prostate cancer treated with first-line androgen deprivation therapies (ADT) will progress to castrate resistant prostate cancer (CRPC). Current ADT treatments and use are associated with upregulation of constitutively active androgen receptor splice variants. Androgen receptor splice variant 567 exon-skipping (ARv567es) is correlated with a marked decrease in 5-year survival in spite of ADT treatment. In our ARv567es mouse models, we have observed a high immune cell infiltrate in places common for mouse prostate cancer metastases such as the lung. Thus, there is an increased need to understand the role of the immune system and ARv567es in prostate cancer metastasis and resistance. Objective: To understand the role of immune cells in metastasis of prostate cancer expressing splice variants. Design: M12 human prostate cancer cells transfected with a plasmid containing ARv567es cDNA were grown in vitro and exposed to Bone Marrow Macrophages (BMM) isolated from C57BL/6 mice femurs. BMM were differentiated into M0, M1, and M2 macrophages. M1 macrophages are thought to attack tumor cells while M2 macrophages promote their growth. The following experiments were performed: proliferation studies (MTS assays), migration studies (scratch assays), and invasion studies (Boyden chambers). Results: Proliferation was significantly higher when M12 ARv567es cells were exposed to M2 conditioned medium as compared to M1 conditioned medium. Scratch assays revealed a significantly increased migration of M12 cells co-cultured with M0 and M2 conditioned medium. Boyden chamber studies demonstrated an increase in migration when M12 cells were exposed to M2 cells. Conclusions and relevance: We demonstrate in vitro evidence to support the current hypothesis of the role of the immune system in prostate cancer metastasis. Overall, our results demonstrate that immune cells, including M2 macrophages, may create a tumor microenvironment that promotes prostate cancer metastasis. Citation Format: Jared HL Hara, Stephen R. Plymate, Cynthia T. Sprenger. The role of immune cells and androgen receptor splice variant 567 exon-skipping in prostate cancer. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr C11.
What are the important health-related quality of life issues in patients diagnosed with indolent lymphoma?
Authors: S. D. Mathias, T. A. Cimms, H. H. Colwell, D. P. Lubeck, K. L. Dawson, J. E. Huang
Journal: Journal of Clinical Oncology (2006)

18574 Background: Numerous treatment options are available for indolent lymphoma (IL), including watchful waiting, each with unique, longer term therapeutic and health-related quality of life (HRQL) issues. No validated HRQL questionnaire currently exists to assess the full range of issues that impact an IL patient’s QoL. We sought to fully assess these important areas to inform decisions about the use of a HRQL questionnaire in clinical studies. Methods: Five focus groups (n = 33), supplemented by in-depth one-on-one telephone interviews (n = 19) were conducted with IL patients across the US. Results: A total of 52 IL patients (65% female; mean age 53 years) participated and completed a questionnaire. Mean time since diagnosis was 51 months; 83% had received active treatment since diagnosis. Participants belonged to one of the following treatment categories: Watchful Waiting (17%), Actively Being Treated (50%), and Previously Treated (33%). Patients identified 4 domains and issues (see Table ) common across all patients regardless of treatment category. Treatment-specific issues included lack of control over the disease with watchful waiting vs. taking control, and actively fighting the disease with a specific treatment. Results from the questionnaire will be presented. Conclusions: Further elucidation of these issues is needed to facilitate HRQL evaluation in future studies and better inform treatment decisions. [Table: see text] [Table: see text]
Hearing loss in children with osteosarcoma
Authors: M. Lewis, S. DuBois, B. Fligor, A. Goorin, H. Grier
Journal: Journal of Clinical Oncology (2007)

9517 Background: Cisplatin is one of the most effective agents against osteosarcoma. Cisplatin is usually administered as a short IV infusion in most contemporary North American osteosarcoma treatment protocols. Ototoxicity from such protocols has not been well defined. The aim of this study was to determine the incidence and the risk factors for hearing loss in children with osteosarcoma. Methods: Eligible patients (pts) in this retrospective cohort study had osteosarcoma diagnosed and treated at our center from 1/1/1995 to 12/31/2004, were 3–18 years of age at diagnosis, and had a normal audiogram prior to the start of chemotherapy. All pts received cisplatin according to either standard practice or current open protocol. Most regimens prescribed a cumulative dose of 480 mg/m 2 over 4 cycles. Pts with hearing loss at lower doses had cisplatin held on an individualized basis. Hearing was evaluated using pure-tone audiometry prior to the start of therapy, before each cycle of cisplatin administration, and off-therapy. The primary endpoint was any hearing loss as defined as &gt; 20 dB decrease in hearing above 4,000 Hz. Fisher's exact test and logistic regression methods were used to identify univariate and independent predictors of hearing loss, respectively. Results: The incidence of hearing loss was 16/40 (40%). Six pts discontinued cisplatin early due to hearing loss. Seven of 9 pts (77.8%) who received cisplatin 120 mg/m 2 as a short IV infusion on 1 day developed hearing loss compared to 9 of 31 (29.0%) pts who received this same dose as two daily infusions (p=0.018). On univariate analyses, age and cumulative cisplatin dose were not predictive of hearing loss. Logistic regression controlling for age, sex, race, and cumulative dose showed that administration of cisplatin 120 mg/m 2 on 1 day compared to 2 days was an independent predictor of hearing loss (odds ratio of 11.6, 95% confidence interval = 1.62–82.87). Conclusions: Cisplatin given as 120 mg/m 2 /dose on 1 day was associated with greater risk of hearing loss than 60 mg/m 2 /dose on 2 days. Cumulative dose and age were not found to be predictors of hearing loss in this relatively small cohort. No significant financial relationships to disclose.
Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.
Authors: Julien Taïeb, Roberto Bordonaro, Salvatore Siena, Libero Ciuffreda, Francesco Di Costanzo, Maria Di Bartolomeo, Anne L. Thomas, Hendrik Kroening, Pilar Garcia Alfonso, Christophe Borg, Yan Moore, Sandrine Brette, Chiara Zilocchi, Florence Joulain, Sarah Naoshy, Pascale Garreau-Laporte, Emmanuelle Dochy, Gérard Lledo, Alberto F. Sobrero
Journal: Journal of Clinical Oncology (2014)

e14560 Background: In the phase 3 VELOUR trial, ziv-aflibercept (Z, known as aflibercept outside the United States) + FOLFIRI gave significant OS benefit vs. FOLFIRI alone in metastatic colorectal cancer (mCRC) patients (pts) previously treated with an oxaliplatin-containing regimen. The results of VELOUR supported initiation of the global Aflibercept Safety and Quality-of-Life (QoL) Program, comprising 2 clinical studies (ASQoP [NCT01571284]; AFEQT [NCT01670721]) that capture utility values derived from QoL instruments and safety data from a population similar to that of VELOUR in a real-life setting. We report QoL and utility value data from the 3rdinterim analysis of the ASQoP/AFEQT studies. Methods: Target recruitment in ASQoP is 900 pts from 150 multiple country sites and for AFEQT, 200 pts from French sites. The EuroQol EQ-5Dx instrument served as the utility measure and the EORTC QLQ-C30 as the generic cancer instrument. The QoL populations were pts evaluable for the respective questionnaire at baseline and ≥1 assessment postbaseline and received ≥1 part of 1 dose of study treatment. Both instruments were self-administered at baseline and at the beginning of every odd treatment cycle. Results: Interim analyses were preplanned to evaluate safety in a real-life setting. At the 3rd interim analysis cutoff date, the EQ-5D population consisted of 317 pts; 60.6% were men, mean age 62 years (range: 20-89), 69.7% had ECOG scores = 0. Mean baseline utility index was 0.76 (95% CI, 0.73-0.78). Utility index remained relatively stable at cycle 3 (in 267 evaluable pts) and up to cycle 11 (in 58 evaluable pts) with a mean (±SD) change from baseline of -0.01 (±0.26) and -0.05 (±0.26), respectively. Mean baseline Global Health Status (GHS) score from EORTC QLQ-C30 was 67.72 (95% CI, 65.48-69.97). Changes from baseline starting at cycle 3 remained in the stable range across subsequent cycles for GHS and functional scales. Conclusions: Trends from this interim analysis suggest relatively stable utility and QoL in mCRC pts treated 2nd line with Z + FOLFIRI. This has important implications in advanced cancer, as pt-reported outcomes provide an informed perspective on health status and well-being. Clinical trial information: NCT01571284.
Bloodspot: A Web Resource Facilitating the Analysis of Transcriptional Programs in Normal and Malignant Hematopoiesis
Authors: Frederik Otzen Bagger, Damir Sasivarevic, Sina Hadi Sohi, Linea Gøricke Laursen, Sachin Pundhir, Ole Winther, Nicolas Rapin, Bo T Porse
Journal: Blood (2015)
The importance of pharmacotherapy monitoring in the outpatient pediactric cancer service.
Authors: A. Livinalli
Journal: Journal of Clinical Oncology (2010)

e19648 Background: Pharmacotherapy monitoring is the professional practice in which the pharmacist is responsible for patient needs with regard to medicines through the detection of drug related problems (DRP).The study aimed to assess the number of pharmacist intervention to patients being treated with oral drugs. Identify the category of DRP, number and type of medications during the cancer treatment. Methods: a retrospective (January 2006-November 2009) analysiswas performed on pharmacy records of 76 patients including new and follow up visits. Evaluating DRP third consensus of Granada was used. Pharmacist provided detailed instructions, assessed understanding of caregiver, evaluated adherence and reviewed for DRP during this period. Results: The sample consisted of 76 patients, median age 9,5 years (1-20). Medicines taken by mouth were in median 11,49 (range 1-32) during the cancer treatment. Most common medications classes were antibiotic (23,54%),antiemetic (10,86%), corticosteroid (7,88), chemotherapy (6,4%), opioid analgesic (4,35%), other (46,97%). During the studies, 19 (25%) patients required of 32 pharmacist intervention. The most common DRP was of category “necessity”(56,25%), followed by “safety”(25%), and “effectiveness”(18,75%). The main therapeutic class involved was antibiotic and chemotherapy followed by corticosteroid. Conclusions: a pediatric medication follow up resulted in 25% of patients requiring specific interventions and 32 DRP identification. This type of intervention can optimize care by identifying the adherence and detect adverse drug events avoiding their serious consequence. These results show that the pharmacist is so important to outpatient than inpatient during the cancer therapy, and we shouldn't pay attention just in the oral chemotherapy, but in the other drugs too. No significant financial relationships to disclose.
Mir-126 and Mir-195-Mediated Control of B Cell Fate in Leukemic and Normal Cells As a Potential Alternative for Transcriptional Factor
Authors: Ai Kotani, Kazuki Okuyama, Bidisha Chanda, Tomokatsu Ikawa, Hiroshi Kawamoto, Kiyoshi Ando, Arinobu Tojo, Harvey F. Lodish
Journal: Blood (2012)
GW26-e4628 Assessment of osteopontin, osteoprotegerin and activated monocytes/macrophages on hypertensive patients with vascular calcification
Authors: Qian Ge, ChengChao Ruan, Yu Ma, QiHong Wu, JiGuang Wang, DingLiang Zhu, Pinjing Gao
Journal: Journal of the American College of Cardiology (2015)
Monitoring of Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities.
Authors: Anna Guidetti, Carmelo Carlo-Stella, Alberto Rocci, Liliana Devizzi, Daniela Sia, Adele Testi, Michele Magni, Massimo Di Nicola, Paola Matteucci, Alessandra Risso, Marco Ruella, Corrado Tarella, Alesandro M. Gianni
Journal: Blood (2008)
Front-Line Therapy with Arsenic Trioxide/All-Trans-Retinoic Acid Combination and Chemotherapy Improves Cure Rates in Newly Diagnosed Patients with Acute Promyelocytic Leukemia
Authors: Jiong Hu, Yuan-fang Liu, Chuan-feng Wu, Guang-biao Zhou, Zhi-Xiang Shen, Jun-min Li, Zhen-Yi Wang, Sai-Juan Chen, Zhu Chen
Journal: Blood (2008)
GW26-e2225 Changes in incidence and risk factors of gestational diabetes mellitus among pregnant women in Shanghai: a comparative study between year 2001 and 2010
Authors: Guanghua Wang, Liang Zheng, Juanli Wu, Jing Wu, Miaomiao Zhao, Siyun Yu, Qiaoyu Jiang, Jie Zhang, Qian Zhou, Jue Li
Journal: Journal of the American College of Cardiology (2015)
Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study
Authors: S.R. Markar, B.J. Noordman, H. Mackenzie, J.M. Findlay, P.R. Boshier, M. Ni, E.W. Steyerberg, A. van der Gaast, M.C.C.M. Hulshof, N. Maynard, M.I. van Berge Henegouwen, B.P.L. Wijnhoven, J.V. Reynolds, J.J.B. Van Lanschot, G.B. Hanna
Journal: Annals of Oncology (2016)

BackgroundThe primary aim of this study was to compare survival from neoadjuvant chemoradiotherapy plus surgery (NCRS) versus neoadjuvant chemotherapy plus surgery (NCS) for the treatment of esophageal or junctional adenocarcinoma. The secondary aims were to compare pathological effects, short-term mortality and morbidity, and to evaluate the effect of lymph node harvest upon survival in both treatment groups.MethodsData were collected from 10 European centers from 2001 to 2012. Six hundred and eight patients with stage II or III oesophageal or oesophago-gastric junctional adenocarcinoma were included; 301 in the NCRS group and 307 in the NCS group. Propensity score matching and Cox regression analyses were used to compensate for differences in baseline characteristics.ResultsNCRS resulted in significant pathological benefits with more ypT0 (26.7% versus 5%;P < 0.001), more ypN0 (63.3% versus 32.1%;P < 0.001), and reduced R1/2 resection margins (7.7% versus 21.8%;P < 0.001). Analysis of short-term outcomes showed no statistically significant differences in 30-day or 90-day mortality, but increased incidence of anastomotic leak (23.1% versus 6.8%;P < 0.001) in NCRS patients.There were no statistically significant differences between the groups in 3-year overall survival (57.9% versus 53.4%; Hazard Ratio (HR)= 0.89, 95%C.I. 0.67-1.17,P = 0.391) nor disease-free survival (52.9% versus 48.9%; HR = 0.90, 95%C.I. 0.69-1.18,P = 0.443). The pattern of recurrence was also similar (P = 0.660). There was a higher lymph node harvest in the NCS group (27 versus 14;P < 0.001), which was significantly associated with a lower recurrence rate and improved disease free survival within the NCS group.ConclusionThe survival differences between NCRS and NCS maybe modest, if present at all, for the treatment of locally advanced esophageal or junctional adenocarcinoma. Future large-scale randomized trials must control and monitor indicators of the quality of surgery, as the extent of lymphadenectomy appears to influence prognosis in patients treated with NCS, from this large multi-center European study.
The Plateau of BCR-ABL Transcript Level ≥0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.
Authors: Katerina Machova Polakova, Vaclava Polivkova, Jana Rulcova, Hana Klamova, Tomas Jurcek, Dana Dvorakova, Daniela Zackova, Zdenek Pospisil, Jirí Mayer, Jana Moravcova
Journal: Blood (2009)
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Authors: Salah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Johannes Meiler, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst, Michael Koenigsmann, Matthias Egger, Nicole Prasnikar, Karel Caca, Jörg Trojan, Uwe M Martens, Andreas Block, Wolfgang Fischbach, Rolf Mahlberg, Michael Clemens, Gerald Illerhaus, Katja Zirlik, Dirk M Behringer, Wolff Schmiegel, Michael Pohl, Michael Heike, Ulrich Ronellenfitsch, Martin Schuler, Wolf O Bechstein, Alfred Königsrainer, Timo Gaiser, Peter Schirmacher, Wael Hozaeel, Alexander Reichart, Thorsten O Goetze, Mark Sievert, Elke Jäger, Stefan Mönig, Andrea Tannapfel
Journal: The Lancet Oncology (2016)
GW26-e1504 The All-Cause Mortality in Hospitalized Patients Associated with Acquired Long QT Syndrome — A Follow-up Study
Authors: Haixu Yu, Li Zhang, Yanli Zhang, Cheng Gou, Yue Chen, Mingjie Deng, Xumin Guan, Binhao Wang, Yushan Wei, Yanzong Yang, Yunlong Xia
Journal: Journal of the American College of Cardiology (2015)
Cost-effectiveness of zoledronic acid versus placebo in the management of skeletal metastases in lung cancer patients (LC pts): Comparison across three European countries
Authors: J. Stephens, S. Kaura, M. F. Botteman
Journal: Journal of Clinical Oncology (2009)

8081 Background: Zoledronic acid (ZOL) reduces the risk of skeletal-related events (SREs) in LC pts with bone metastases. The present retrospective analysis compared the economic impact of ZOL in LC pts in France, Germany, and the United Kingdom (UK). Methods: Estimated direct costs and quality-adjusted life-years (QALYs) experienced by LC pts with bone metastases receiving placebo (PBO) or ZOL were modeled and compared. Overall survival (OS), SRE incidence, and number of infusions administered were obtained from a 21-mo randomized clinical trial comparing the proportion of pts who experienced an on-study SRE with 4 mg ZOL or PBO every 3 wk (Rosen et al. JCO. 2003). Costs of treatments and SREs were estimated using national reimbursement listings (eg, diagnosis-related groups), private databases, and published literature. Mean number of SREs was calculated by multiplying mean SRE rate by OS for LC pts in the study. For QALYs, OS was multiplied by a utility factor of 0.53. Consistent with similar economic analyses, it was assumed that quality of life (QOL) decreased 20% to 80% (depending on the SRE type) for 1 mo after each SRE experienced. Sensitivity analyses were performed to test the effects of alternate scenarios, with &lt; €30,000/QALY considered cost-effective. Results: During the median OS of 179 days, PBO pts (n = 120) experienced a mean of 2.07 SREs vs 1.32 SREs among ZOL pts (n = 124). QALYs were estimated at 0.352/pt (ZOL pts) and 0.335/pt (PBO pts). Use of ZOL resulted in a net increase of 0.017 QALY/pt vs PBO. ZOL drug-related costs were €1,610, €1,510 and €1,597 per pt in France, Germany, and the UK, respectively. Use of ZOL resulted in reductions in SRE costs of €2,221, €2,031, and €2,014 per pt, respectively. Overall, ZOL saved €598 per pt in France, €521 in Germany, and €417 in the UK. In sensitivity analyses, ZOL was cost-effective under a variety of scenarios (total range, -€98,356 to +€34,052 per QALY). Conclusions: ZOL leads to fewer SREs, better estimated QOL, and lower estimated costs relative to PBO in German, French, and UK LC pts with bone metastases. Use of ZOL in these populations is therefore cost-saving and highly cost-effective. [Table: see text]
Liver Histology, Liver Iron Concentration (LIC), and Serum Ferritin in a Large Cohort of Chronically Transfused Children with Sickle Cell Anemia: Limitations of LIC As a Marker for Hepatic Injury and Ferritin as An Indicator for Chelation Initiation
Authors: Erika Vogel, Jeffrey D. Lebensburger, Shuting Bai, Naomi Fineberg, Lee Hilliard, Naren Vadlamudi, Reed Dimmit, David Kelly, Thomas H. Howard
Journal: Blood (2011)
Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis through Histone Acetylation and Upregulation of Annexin A1 in AML1-ETO Expressing Kasumi-1 Cells.
Authors: Yoko Tabe, Rooha Contractor, Susanne Radke, Michael Andreeff, Marina Konopleva
Journal: Blood (2004)
EB10, an Anti-FLT3 Monoclonal Antibody, Selectively Targets ALL Cell Lines and Primary ALL Blasts without Interfering with Normal Hematopoiesis.
Authors: Obdulio Piloto, Patrick Brown, Li Li, Bao Nguyen, Kyu-Tae Kim, David Huso, Yiwen Li, Hongli Li, Mei-Nai Wang, Larry Witte, Daniel J. Hicklin, Donald Small
Journal: Blood (2004)